Literature DB >> 1395223

Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin.

Y Tomer1, Y Shoenfeld.   

Abstract

A 23-year-old woman with SLE was admitted because of severe psychosis manifested by depression, delusions and the inability to perform minimal daily activities. The patient refused treatment with steroids, but was later convinced to try treatment with intravenous immunoglobulin (IVIG). Following treatment with IVIG a marked improvement was noted in her mental status and she was discharged. During a follow-up period of 18 months she resumed normal life; she does not receive any drugs currently and no psychiatric abnormalities have been noted. It is suggested that IVIG may be considered in the treatment of lupus cerebritis, especially when serious complications develop and other treatment modalities are ineffective.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1395223

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  18 in total

Review 1.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 2.  [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

Review 3.  Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Authors:  Gisele Zandman-Goddard; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases.

Authors:  Gisele Zandman-Goddard; Alexander Krauthammer; Yair Levy; Pnina Langevitz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

5.  Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.

Authors:  G Zandman-Goddard; M Blank; P Langevitz; L Slutsky; M Pras; Y Levy; O Shovman; T Witte; A Doria; J Rovensky; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

Review 6.  Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders.

Authors:  Andreas Steinbrecher; Peter Berlit
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 7.  Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature.

Authors:  Aaron M Milstone; Kevin Meyers; Josephine Elia
Journal:  Clin Rheumatol       Date:  2005-01-21       Impact factor: 2.980

8.  Autoimmune multiorgan involvement in elderly men is it SLE?

Authors:  A Aharon; G Zandman-Goddard; Y Shoenfeld
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

9.  Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea.

Authors:  I Lazurova; Z Macejova; K Benhatchi; M Oetterová; E Antolová; R A Asherson; J Rovensky
Journal:  Clin Rheumatol       Date:  2007-05-09       Impact factor: 2.980

10.  Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate.

Authors:  M Blank; J Manosroi; Y Tomer; A Manosroi; J Kopolovic; S Charcon-Polak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.